Zacks Research Analysts Boost Earnings Estimates for Glaukos

Glaukos Co. (NYSE:GKOS) – Investment analysts at Zacks Research raised their Q4 2026 earnings per share (EPS) estimates for shares of Glaukos in a research note issued on Thursday, March 13th. Zacks Research analyst I. Bandyopadhyay now forecasts that the medical instruments supplier will earn $0.06 per share for the quarter, up from their prior forecast of $0.03. The consensus estimate for Glaukos’ current full-year earnings is ($1.08) per share. Zacks Research also issued estimates for Glaukos’ FY2027 earnings at $0.82 EPS.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). The company had revenue of $105.50 million for the quarter, compared to the consensus estimate of $100.72 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%.

Several other equities analysts also recently weighed in on GKOS. Morgan Stanley downgraded shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 target price for the company. in a research note on Monday, December 2nd. Piper Sandler reissued an “overweight” rating and set a $180.00 target price (up previously from $140.00) on shares of Glaukos in a report on Monday, January 27th. Truist Financial lifted their price target on Glaukos from $152.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. Citigroup raised Glaukos from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $132.00 to $162.00 in a report on Wednesday, December 11th. Finally, Mizuho upgraded Glaukos from a “neutral” rating to an “outperform” rating and upped their price target for the company from $140.00 to $200.00 in a research report on Wednesday, February 19th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $163.25.

Glaukos Price Performance

Shares of NYSE GKOS opened at $103.12 on Monday. The firm has a market cap of $5.83 billion, a price-to-earnings ratio of -35.93 and a beta of 0.99. The stock has a fifty day simple moving average of $139.82 and a two-hundred day simple moving average of $137.49. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. Glaukos has a 1-year low of $85.04 and a 1-year high of $163.71.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Glaukos in the fourth quarter worth $12,367,000. Forum Financial Management LP purchased a new position in shares of Glaukos in the fourth quarter valued at about $211,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Glaukos by 20.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 162,326 shares of the medical instruments supplier’s stock valued at $24,339,000 after acquiring an additional 27,889 shares during the period. State of Wyoming raised its stake in shares of Glaukos by 2.3% during the fourth quarter. State of Wyoming now owns 3,245 shares of the medical instruments supplier’s stock valued at $487,000 after acquiring an additional 72 shares during the last quarter. Finally, Thornburg Investment Management Inc. boosted its holdings in shares of Glaukos by 18.4% during the fourth quarter. Thornburg Investment Management Inc. now owns 45,583 shares of the medical instruments supplier’s stock worth $6,835,000 after purchasing an additional 7,072 shares during the period. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Insider Transactions at Glaukos

In other Glaukos news, Director Gilbert H. Kliman sold 10,000 shares of the stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $150.28, for a total transaction of $1,502,800.00. Following the transaction, the director now directly owns 32,336 shares in the company, valued at $4,859,454.08. This trade represents a 23.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Tomas Navratil sold 3,416 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the sale, the insider now owns 72,437 shares of the company’s stock, valued at approximately $10,658,380.18. The trade was a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 16,744 shares of company stock valued at $2,504,131 in the last quarter. Insiders own 6.40% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.